NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing antiviral drugs called nanoviricides, based on nanomedicine platform technology. Its lead drug candidate, NV-387, has completed Phase Ia/Ib human clinical safety and tolerability trials and is ready for Phase II efficacy trials. NV-387 targets COVID-19, RSV, Influenza, Orthopoxvirus (Smallpox/MPox), and Measles. The company has no revenues or commercialized products and operates from Shelton, Connecticut.
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-29 | 2025-06-30 | 0001104659-25-094527 | EDGAR | 87K words |
| 2024-09-27 | 2024-06-30 | 0001410578-24-001650 | EDGAR | — |
| 2023-10-13 | 2023-06-30 | 0001410578-23-002146 | EDGAR | — |
| 2022-10-13 | 2022-06-30 | 0001410578-22-002878 | EDGAR | — |
| 2021-10-12 | 2021-06-30 | 0001104659-21-125343 | EDGAR | — |
| 2020-10-13 | 2020-06-30 | 0001104659-20-114577 | EDGAR | — |
| 2019-08-23 | 2019-06-30 | 0001144204-19-041547 | EDGAR | — |
| 2018-10-12 | 2018-06-30 | 0001144204-18-053665 | EDGAR | — |
| 2017-09-28 | 2017-06-30 | 0001144204-17-050412 | EDGAR | — |
| 2016-09-16 | 2016-06-30 | 0001144204-16-124276 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001104659-26-016476 | EDGAR | 35K words |
| 2025-11-14 | 2025-09-30 | 0001104659-25-112608 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001410578-25-001336 | EDGAR | — |
| 2025-02-14 | 2024-12-31 | 0001410578-25-000140 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001410578-24-001991 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001410578-24-000843 | EDGAR | — |
| 2024-02-14 | 2023-12-31 | 0001410578-24-000048 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001410578-23-002484 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001410578-23-001235 | EDGAR | — |
| 2023-02-14 | 2022-12-31 | 0001410578-23-000129 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001410578-22-003398 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001410578-22-001688 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-11-26 | 0001104659-25-116457 | EDGAR | 1K words |
| 2025-11-14 | 0001104659-25-112644 | EDGAR | — |
| 2025-10-01 | 0001104659-25-095676 | EDGAR | — |
| 2024-12-12 | 0001104659-24-128066 | EDGAR | — |
| 2024-08-09 | 0001104659-24-087828 | EDGAR | — |
| 2024-04-05 | 0001104659-24-044367 | EDGAR | — |
| 2024-02-16 | 0001104659-24-024973 | EDGAR | — |
| 2024-01-19 | 0001104659-24-005254 | EDGAR | — |
| 2023-11-07 | 0001104659-23-114862 | EDGAR | — |
| 2023-09-01 | 0001104659-23-097802 | EDGAR | — |
249 total filings indexed. 217 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001379006 |
| Ticker | NNVC |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Shelton, Connecticut |
| Website | https://www.nanoviricides.com |
| Listed | 2005-07-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report